Menu
MSE PRO tert-Butyl 7-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate, ≥98.0% Purity - MSE Supplies LLC

MSE PRO tert-Butyl 7-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate, ≥98.0% Purity

SKU: CM1399

  • $ 39995
  • Save $ 4605


MSE PRO™ tert-Butyl 7-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate, ≥98.0% Purity

MSE PRO™ tert-Butyl 7-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate is a versatile and valuable synthetic intermediate for organic synthesis. As a spirocyclic compound, it possesses a unique rigid bicyclic structure with a fused diazaspiro ring system. This structural motif is prevalent in many bioactive molecules and drug candidates, making it an attractive building block for medicinal chemistry applications. The presence of the tert-butyl carbamate protecting group allows for selective deprotection under mild acidic conditions, revealing a reactive amine functionality for further derivatization. This feature enables the controlled introduction of diverse substituents, facilitating the synthesis of complex heterocyclic scaffolds with potential biological activities.

MSE Supplies offers various N-heterocyclic drug small molecules and other chemical reagents. Please contact us for bulk orders.

Technical Specifications:

CAS No. 1234616-51-3
Chemical name tert-Butyl 7-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate
Synonym(s)
  • tert-butyl-6-oxo-2,7-diazaspiro[3.4]octane-2-carboxylate

  • 2,6-Diazaspiro[3.4]octane-2-carboxylic acid, 7-oxo-, 1,1-dimethylethyl ester
Molecular formula C11H18N2O3             
Pack size 5 g (CM1399); 25 g (CM1400)
Molecular weight 226.27 g/mol
Purity 98.22% (LCMS)
Boiling point  399.1±42.0 °C (Predicted) 
Density   1.20±0.1 g/cm
pKa 16.10±0.20 (Predicted) 
Appearance White to off-white solid 
Storage  Store at room temperature


References:

[1] Fu, K., Xu, W., Yang, R., Zhao, H., Xu, H., Wei, Y., ... & Xiong, B. (2023). 2, 6-diazaspiro [3.4] octan-7-one derivatives as potent sigma-1 receptor antagonists that enhanced the antinociceptive effect of morphine and rescued morphine tolerance. European Journal of Medicinal Chemistry249, 115178.

[2] Martínez-Viturro, C. M., Trabanco, A. A., Royes, J., Fernández, E., Tresadern, G., Vega, J. A., ... & Bartolomé-Nebreda, J. M. (2020). Diazaspirononane nonsaccharide inhibitors of O-GlcNAcase (OGA) for the treatment of neurodegenerative disorders. Journal of medicinal chemistry63(22), 14017-14044.